Search
for
Sort by
Research 631–660 of 1000+
- Long-term effectiveness and safety of topical finasteride 0.25% monotherapy in male androgenetic alopecia: a 52-week real-world retrospective study
- Baseline Neutrophil-to-Lymphocyte Ratio Stratifies Early Trichoscopic Response to Platelet-Rich Plasma–Based Regimens in Non-Scarring Alopecia: A Real-World Cohort with Internal Validation Using an Interpretable Neural Network
- Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
- Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
- Longitudinal biomarker trajectories accompanying trichoscopic change after PRP-based regimens for alopecia: a complementary multi-marker analysis of a real-world cohort.
- P0689 High-dose IV iron safely and effectively treats IBD-associated anaemia regardless of inflammatory activity – real-life evidence from Germany
- Trichoscopic Markers and Clinical Response Patterns With Ritlecitinib in Severe Alopecia Areata: 24‐Week Outcomes From a Prospective Real‐World Cohort
- Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
- 63532 Impact of Eyebrow and Eyelash Hair Loss on Health-Related Quality of Life Among Patients with Alopecia Areata: Results From a Real-World Survey in 5 European Countries
- Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports
- Effectiveness of Baricitinib in Alopecia Areata Patients With a Current Episode Lasting Longer Than 8 Years: An Italian Multicenter Real‐Life Experience in the Lazio Region
- Effectiveness of Generic Tofacitinib in the Treatment of Patients with Mild Alopecia Areata in China: A Retrospective Real-World Study
- Treatment of Lichen Planopilaris and Frontal Fibrosing Alopecia: A Retrospective, Real-Life Analysis in a Tertiary Center in Germany
- Transarterial chemoembolization (TACE) combined with donafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A real-world clinical study.
- Iron Supplementation May Improve the Patient’s Level of Satisfaction in Not-Low-Ferritin Telogen Effluvium: A Real-Life Observational Study
- Effectiveness and Predictive Factors of Response to Tofacitinib Therapy in 125 Patients with Alopecia Areata: A Single-centre Real-world Retrospective Study
- Degree of Alignment Between Japanese Patients and Physicians on Alopecia Areata Disease Severity and Treatment Satisfaction: A Real-World Survey
- BH15 Efficacy and safety of baricitinib in the management of severe alopecia areata over a 6-month period: a real-world experience
- Growth factor concentrate therapy for management of hair loss: a prospective, real-world study
- P47 Efficacy and safety of antifungal treatment in fungal asthma; a real life study
- FRI0310 Achievement of low disease activity in lupus patients treated with belimumab is independent of serologic status at baseline: a real-life observational study
- Abstract P5-21-05: ERALOP study: Post adjuvant FEC - docetaxel chemotherapy for early breast cancer: Hair regrowth in the real life
- Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: Prospective, multicenter, real‐world data from a Greek registry
- Iron and hair loss in women; what is deficiency? This is the real question!
- Self-healing and shape-adaptive nanocomposite hydrogels with anti-inflammatory, antioxidant, antibacterial activities and hemostasis for real-time visual regeneration of diabetic wounds
- Circulating monocytes as a marker of response to adalimumab in patients with hidradenitis suppurativa: A single institution, real-world cohort study
- Drugs linked to blepharitis, meibomian gland dysfunction, and chalazion: a real-world, population-based pharmacovigilance analysis
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Interest of an anti-hair loss serum containing Silybum marianum extract, manganese pyrrolidone carboxylic acid (PCA), and a Lespedeza capitata extract in the management of post-cancer treatment alopecia: an international real-world study